# Fulvio Mavilio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7400520/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 189 papers | 18,056 citations | 16411 64 h-index | 12910 131 g-index |
| 190 all docs | 190 docs citations | 190 times ranked | 13989 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Muscleâ€directed gene therapy corrects Pompe disease and uncovers speciesâ€specific GAA immunogenicity. EMBO Molecular Medicine, 2022, 14, e13968. | 3.3 | 17 |
| 2 | Correction of Î²-thalassemia by CRISPR/Cas9 editing of the Î±-globin locus in human hematopoietic stem cells. Blood Advances, 2021, 5, 1137-1153. | 2.5 | 41 |
| 3 | Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. Viruses, 2021, 13, 1526. | 1.5 | 27 |
| 4 | Clinical Results of the Drepaglobe Trial for Sickle Cell Disease Patients. Blood, 2021, 138, 1854-1854. | 0.6 | 9 |
| 5 | Editing a Î³-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Science Advances, 2020, 6, . | 4.7 | 91 |
| 6 | Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID. Molecular Therapy - Methods and Clinical Development, 2019, 15, 232-245. | 1.8 | 18 |
| 7 | Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Molecular Therapy, 2019, 27, 137-150. | 3.7 | 97 |
| 8 | Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Molecular Therapy, 2018, 26, 1137-1153. | 3.7 | 53 |
| 9 | The Pharmacology of Gene and Cell Therapy. Molecular Therapy - Methods and Clinical Development, 2018, 8, 181-182. | 1.8 | 5 |
| 10 | Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency. Molecular Therapy - Methods and Clinical Development, 2018, 9, 257-269. | 1.8 | 38 |
| 11 | Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human Î²-globin locus. Blood, 2018, 131, 1960-1973. | 0.6 | 156 |
| 12 | Interactions between Retroviruses and the Host Cell Genome. Molecular Therapy - Methods and Clinical Development, 2018, 8, 31-41. | 1.8 | 57 |
| 13 | Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling Î²AS3 Globin for Gene Therapy for Sickle Cell Disease. Molecular Therapy - Methods and Clinical Development, 2018, 11, 167-179. | 1.8 | 16 |
| 14 | Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for Î²-Thalassemia. Molecular Therapy - Methods and Clinical Development, 2018, 11, 9-28. | 1.8 | 21 |
| 15 | Gene Therapy for Hemoglobinopathies. Human Gene Therapy, 2018, 29, 1106-1113. | 1.4 | 34 |
| 16 | Gene Therapy for Sickle Cell Disease:A Lentiviral Vector Comparison Study. Human Gene Therapy, 2018, 29, 1153-1166. | 1.4 | 33 |
| 17 | An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype. Molecular Therapy - Methods and Clinical Development, 2018, 10, 268-280. | 1.8 | 20 |
| 18 | ExÂVivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair. Molecular Therapy - Nucleic Acids, 2018, 12, 554-567. | 2.3 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. Molecular Therapy - Nucleic Acids, 2017, 7, 11-19. | 2.3 | 44 |
| 20 | Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Molecular Therapy, 2017, 25, 839-854. | 3.7 | 81 |
| 21 | Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry. Gene Therapy, 2017, 24, 590-592. | 2.3 | 11 |
| 22 | Gene Therapy Approaches to Hemoglobinopathies. Hematology/Oncology Clinics of North America, 2017, 31, 835-852. | 0.9 | 49 |
| 23 | Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood, 2017, 130, 1327-1335. | 0.6 | 83 |
| 24 | Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nature Communications, 2017, 8, 16105. | 5.8 | 175 |
| 25 | Retroviral Scanning: Mapping MLV Integration Sites to Define Cell-specific Regulatory Regions. Journal of Visualized Experiments, 2017, , . | 0.2 | 0 |
| 26 | Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates. Translational Research, 2017, 188, 40-57.e4. | 2.2 | 21 |
| 27 | Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16060. | 1.8 | 41 |
| 28 | Dynamic Transcriptional and Epigenetic Regulation of Human Epidermal Keratinocyte Differentiation. Stem Cell Reports, 2016, 6, 618-632. | 2.3 | 55 |
| 29 | Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment. Scientific Reports, 2016, 6, 24724. | 1.6 | 18 |
| 30 | A single epidermal stem cell strategy for safe ex vivo gene therapy. EMBO Molecular Medicine, 2015, 7, 380-393. | 3.3 | 40 |
| 31 | Perspectives on Best Practices for Gene Therapy Programs. Human Gene Therapy, 2015, 26, 127-133. | 1.4 | 14 |
| 32 | Nuclear architecture dictates HIV-1 integration site selection. Nature, 2015, 521, 227-231. | 13.7 | 277 |
| 33 | Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome. JAMA - Journal of the American Medical Association, 2015, 313, 1550. | 3.8 | 327 |
| 34 | Genome-Wide Definition of Promoter and Enhancer Usage during Neural Induction of Human Embryonic Stem Cells. PLoS ONE, 2015, 10, e0126590. | 1.1 | 4 |
| 35 | Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells. Genes, 2014, 5, 415-429. | 1.0 | 23 |
| 36 | Genomic Analysis of Sleeping Beauty Transposon Integration in Human Somatic Cells. PLoS ONE, 2014, 9, e112712. | 1.1 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy. Science Translational Medicine, 2014, 6, 220ra10. | 5.8 | 141 |
| 38 | Repairing Without Cutting: A Safer Alternative to Gene Correction?. Molecular Therapy, 2014, 22, 690-691. | 3.7 | 3 |
| 39 | IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood, 2013, 121, 573-584. | 0.6 | 455 |
| 40 | Mechanisms of Retroviral Integration and Mutagenesis. Human Gene Therapy, 2013, 24, 119-131. | 1.4 | 94 |
| 41 | Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. Molecular Therapy, 2013, 21, 266-268. | 3.7 | 12 |
| 42 | Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication. Virology, 2013, 440, 8-18. | 1.1 | 139 |
| 43 | Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes. Gene Therapy, 2013, 20, 949-957. | 2.3 | 20 |
| 44 | RD2-MolPack-Chim3,a Packaging Cell Line for Stable Production of Lentiviral Vectors for Anti-HIV Gene Therapy. Human Gene Therapy Methods, 2013, 24, 228-240. | 2.1 | 34 |
| 45 | Targeted Gene Addition in Human Epithelial Stem Cells by Zinc-finger Nuclease-mediated Homologous Recombination. Molecular Therapy, 2013, 21, 1695-1704. | 3.7 | 53 |
| 46 | Genotoxic Signature in Cord Blood Cells of Newborns Exposed In Utero to a Zidovudine-Based Antiretroviral Combination. Journal of Infectious Diseases, 2013, 208, 235-243. | 1.9 | 34 |
| 47 | Deletion of the LTR Enhancer/Promoter Has No Impact on the Integration Profile of MLV Vectors in Human Hematopoietic Progenitors. PLoS ONE, 2013, 8, e55721. | 1.1 | 16 |
| 48 | Gene Therapy of Skin Adhesion Disorders (Mini Review). Current Pharmaceutical Biotechnology, 2012, 13, 1868-1876. | 0.9 | 3 |
| 49 | Gene therapies need new development models. Nature, 2012, 490, 7-7. | 13.7 | 13 |
| 50 | Preclinical Corrective Gene Transfer in Xeroderma Pigmentosum Human Skin Stem Cells. Molecular Therapy, 2012, 20, 798-807. | 3.7 | 44 |
| 51 | Alternative Splicing Caused by Lentiviral Integration in the Human Genome. Methods in Enzymology, 2012, 507, 155-169. | 0.4 | 6 |
| 52 | Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. Journal of Clinical Investigation, 2012, 122, 1653-1666. | 3.9 | 134 |
| 53 | The GATA1-HS2 Enhancer Allows Persistent and Position-Independent Expression of a Î²-globin Transgene. PLoS ONE, 2011, 6, e27955. | 1.1 | 23 |
| 54 | Correction of Murine SCID-X1 by Lentiviral Gene Therapy Using a Codon-optimized IL2RG Gene and Minimal Pretransplant Conditioning. Molecular Therapy, 2011, 19, 1867-1877. | 3.7 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Risk assessment in skin gene therapy: viralâ€“cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Therapy, 2011, 18, 674-681. | 2.3 | 49 |
| 56 | Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. Molecular Therapy, 2011, 19, 2031-2039. | 3.7 | 48 |
| 57 | Estimated Comparative Integration Hotspots Identify Different Behaviors of Retroviral Gene Transfer Vectors. PLoS Computational Biology, 2011, 7, e1002292. | 1.5 | 17 |
| 58 | The Importance of Be(ginn)Ing Naiˆve: Implications for Cancer Immune-Gene Therapy. Blood, 2011, 118, 2052-2052. | 0.6 | 0 |
| 59 | High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood, 2010, 116, 5507-5517. | 0.6 | 150 |
| 60 | Correction of Î²â€thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Molecular Medicine, 2010, 2, 315-328. | 3.3 | 82 |
| 61 | Gene therapy: back on track?. EMBO Reports, 2010, 11, 75-75. | 2.0 | 4 |
| 62 | High-Definition Mapping of Retroviral Integration Sites Defines the Fate of Allogeneic T Cells After Donor Lymphocyte Infusion. PLoS ONE, 2010, 5, e15688. | 1.1 | 39 |
| 63 | Human epithelial stem cells in corneal regeneration and epidermal gene therapy. FASEB Journal, 2010, 24, 64.4. | 0.2 | 0 |
| 64 | Integration Site Selection by Retroviruses and Retroviral Vectors. , 2010, , 211-241. | | 0 |
| 65 | Transcriptional Enhancers Induce Insertional Gene Deregulation Independently From the Vector Type and Design. Molecular Therapy, 2009, 17, 851-856. | 3.7 | 79 |
| 66 | Tracking Gene-Modified T Cells In Vivo. Methods in Molecular Biology, 2009, 506, 391-401. | 0.4 | 1 |
| 67 | PPARÎ´ is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation. Carcinogenesis, 2009, 30, 230-237. | 1.3 | 7 |
| 68 | Epithelial stem cells in corneal regeneration and epidermal gene therapy. Journal of Pathology, 2009, 217, 217-228. | 2.1 | 106 |
| 69 | Gene therapy of inherited skin adhesion disorders: a critical overview. British Journal of Dermatology, 2009, 161, 19-24. | 1.4 | 48 |
| 70 | Comprehensive genomic access to vector integration in clinical gene therapy. Nature Medicine, 2009, 15, 1431-1436. | 15.2 | 173 |
| 71 | Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood, 2009, 114, 3546-3556. | 0.6 | 65 |
| 72 | Transcription Factor Binding Sites Are Genetic Determinants of Retroviral Integration in the Human Genome. PLoS ONE, 2009, 4, e4571. | 1.1 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Role of CD34 Antigen in Myeloid Differentiation of Human Hematopoietic Progenitor Cells. Stem Cells, 2008, 26, 950-959. | 1.4 | 30 |
| 74 | Genetic modification of somatic stem cells. EMBO Reports, 2008, 9, S64-9. | 2.0 | 9 |
| 75 | IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Therapy, 2008, 15, 504-515. | 2.3 | 101 |
| 76 | Absence of an intrathecal immune reaction to a helper-dependent adenoviral vector delivered into the cerebrospinal fluid of non-human primates. Gene Therapy, 2008, 15, 233-238. | 2.3 | 18 |
| 77 | Gene therapy of inherited skin adhesion disorders. Drug Discovery Today: Therapeutic Strategies, 2008, 5, 249-254. | 0.5 | 0 |
| 78 | Correction of Laminin-5 Deficiency in Human Epidermal Stem Cells by Transcriptionally Targeted Lentiviral Vectors. Molecular Therapy, 2008, 16, 1977-1985. | 3.7 | 60 |
| 79 | C/EBPÎ´ regulates cell cycle and self-renewal of human limbal stem cells. Journal of Cell Biology, 2007, 177, 1037-1049. | 2.3 | 181 |
| 80 | Long-term Engraftment of Single Genetically Modified Human Epidermal Holoclones Enables Safety Pre-assessment of Cutaneous Gene Therapy. Molecular Therapy, 2007, 15, 1670-1676. | 3.7 | 64 |
| 81 | Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood, 2007, 110, 1770-1778. | 0.6 | 248 |
| 82 | Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. Journal of Clinical Investigation, 2007, 117, 2233-2240. | 3.9 | 231 |
| 83 | Transduction of Human Hematopoietic Stem Cells by Lentiviral Vectors Pseudotyped with the RD114-TR Chimeric Envelope Glycoprotein. Human Gene Therapy, 2007, 18, 811-820. | 1.4 | 27 |
| 84 | Gene therapy in combination with tissue engineering to treat epidermolysis bullosa. Expert Opinion on Biological Therapy, 2006, 6, 367-378. | 1.4 | 31 |
| 85 | Towards a Gene Therapy Clinical Trial for Epidermolysis Bullosa. Reviews on Recent Clinical Trials, 2006, 1, 155-162. | 0.4 | 11 |
| 86 | Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nature Medicine, 2006, 12, 1397-1402. | 15.2 | 593 |
| 87 | Site-Specific Integration into the Human Genome: Ready for Clinical Application?. Rejuvenation Research, 2006, 9, 446-449. | 0.9 | 8 |
| 88 | Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1457-1462. | 3.3 | 172 |
| 89 | Clonal Analyses of Retroviral Vector Integrations in ADA-SCID Patients Treated with Stem Cell Gene Therapy.. Blood, 2006, 108, 3249-3249. | 0.6 | 1 |
| 90 | Genetic modification of human hematopoietic stem cells. Rendiconti Lincei, 2005, 16, 99-107. | 1.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Competitive Engraftment of Hematopoietic Stem Cells Genetically Modified with a Truncated Erythropoietin Receptor. Human Gene Therapy, 2005, 16, 594-608. | 1.4 | 13 |
| 92 | T Lymphocytes Transduced with a Lentiviral Vector Expressing F12-vif Are Protected from HIV-1 Infection in an APOBEC3G-Independent Manner. Molecular Therapy, 2005, 12, 697-706. | 3.7 | 20 |
| 93 | Gene therapy approaches for epidermolysis bullosa. Clinics in Dermatology, 2005, 23, 430-436. | 0.8 | 30 |
| 94 | Stem cell plasticity: time for a reappraisal?. Haematologica, 2005, 90, 360-81. | 1.7 | 25 |
| 95 | Site-Specific Integration of Functional Transgenes into the Human Genome by Adeno/AAV Hybrid Vectors. Molecular Therapy, 2004, 10, 660-670. | 3.7 | 92 |
| 96 | The future of gene therapy. Nature, 2004, 427, 779-781. | 13.7 | 262 |
| 97 | French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Journal of Gene Medicine, 2003, 5, 82-84. | 1.4 | 30 |
| 98 | Safety of retroviral gene marking with a truncated NGF receptor. Nature Medicine, 2003, 9, 367-369. | 15.2 | 169 |
| 99 | The Choice of a Suitable Lentivirus Vector. , 2003, 229, 17-27. | | 8 |
| 100 | Transcriptional Targeting of Lentiviral Vectors by Long Terminal Repeat Enhancer Replacement. Journal of Virology, 2002, 76, 3996-4007. | 1.5 | 52 |
| 101 | Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1341-1346. | 3.3 | 431 |
| 102 | Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy?. Neuromuscular Disorders, 2002, 12, S7-S10. | 0.3 | 43 |
| 103 | High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood, 2001, 98, 2664-2672. | 0.6 | 106 |
| 104 | Failure to correct murine muscular dystrophy. Nature, 2001, 411, 1014-1015. | 13.7 | 137 |
| 105 | The Recruitment of SOX/OCT Complexes and the Differential Activity of HOXA1 and HOXB1 Modulate the Hoxb1Auto-regulatory Enhancer Function. Journal of Biological Chemistry, 2001, 276, 20506-20515. | 1.6 | 61 |
| 106 | Toward Epidermal Stem Cell-Mediatedex VivoGene Therapy of Junctional Epidermolysis Bullosa. Human Gene Therapy, 2000, 11, 2283-2287. | 1.4 | 58 |
| 107 | Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective?. Journal of Clinical Investigation, 2000, 105, 1669-1674. | 3.9 | 131 |
| 108 | Transcriptional Targeting of Retroviral Vectors to the Erythroblastic Progeny of Transduced Hematopoietic Stem Cells. Blood, 1999, 93, 3276-3285. | 0.6 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Reversible Immortalization of Human Myogenic Cells by Site-Specific Excision of a Retrovirally Transferred Oncogene. Human Gene Therapy, 1999, 10, 1607-1617. | 1.4 | 48 |
| 110 | The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes and Development, 1999, 13, 946-953. | 2.7 | 214 |
| 111 | Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Blood, 1999, 93, 3276-85. | 0.6 | 17 |
| 112 | Prep1, a novel functional partner of Pbx proteins. EMBO Journal, 1998, 17, 1423-1433. | 3.5 | 159 |
| 113 | The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO Journal, 1998, 17, 1434-1445. | 3.5 | 193 |
| 114 | Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors. Science, 1998, 279, 1528-1530. | 6.0 | 2,541 |
| 115 | Definition of the Transcriptional Activation Domains of Three Human HOX Proteins Depends on the DNA-Binding Context. Molecular and Cellular Biology, 1998, 18, 6201-6212. | 1.1 | 41 |
| 116 | High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies.. Journal of Clinical Investigation, 1998, 101, 2119-2128. | 3.9 | 127 |
| 117 | Retroviral Vectors for Human Gene Therapy. , 1998, , 119-132. | | 0 |
| 118 | HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia. Science, 1997, 276, 1719-1724. | 6.0 | 1,146 |
| 119 | Functional dissection of a transcriptionally active, target-specific Hox-Pbx complex. EMBO Journal, 1997, 16, 3644-3654. | 3.5 | 100 |
| 120 | Anti-HIV Viral Interference Induced by Retroviral Vectors Expressing a Nonproducer HIV-1 Variant. Acta Haematologica, 1996, 95, 199-203. | 0.7 | 10 |
| 121 | HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation.. EMBO Journal, 1996, 15, 4981-4991. | 3.5 | 216 |
| 122 | Clonal analysis of stably transduced human epidermal stem cells in culture.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10371-10376. | 3.3 | 164 |
| 123 | In vitro and transgenic analysis of a human HOXD4 retinoid-responsive enhancer. Development (Cambridge), 1996, 122, 1895-1907. | 1.2 | 74 |
| 124 | HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO Journal, 1996, 15, 4981-91. | 3.5 | 96 |
| 125 | A Retroviral Vector Containing a Muscle-Specific Enhancer Drives Gene Expression Only in Differentiated Muscle Fibers. Human Gene Therapy, 1995, 6, 733-742. | 1.4 | 64 |
| 126 | Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. Human Gene Therapy, 1995, 6, 813-819. | 1.4 | 137 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Retinoic acid induces stage-specific antero-posterior transformation of rostral central nervous system. Mechanisms of Development, 1995, 51, 83-98. | 1.7 | 143 |
| 128 | Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients. Science, 1995, 270, 470-475. | 6.0 | 775 |
| 129 | A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. Journal of Virology, 1995, 69, 6618-6626. | 1.5 | 13 |
| 130 | Myogenic conversion of mammalian fibroblasts induced by differentiating muscle cells. Journal of Cell Science, 1995, 108, 2733-2739. | 1.2 | 50 |
| 131 | The thyroid transcription factor-1 gene is a candidate target for regulation by Hox proteins.. EMBO Journal, 1994, 13, 3339-3347. | 3.5 | 66 |
| 132 | Peripheral blood lymphocytes as target cells of retroviral vector- mediated gene transfer. Blood, 1994, 83, 1988-1997. | 0.6 | 234 |
| 133 | Specificity of HOX protein function depends on DNA-protein and protein-protein interactions, both mediated by the homeo domain.. Genes and Development, 1994, 8, 732-744. | 2.7 | 120 |
| 134 | Inhibition of retinoic acid-induced activation of 3' human HOXB genes by antisense oligonucleotides affects sequential activation of genes located upstream in the four HOX clusters.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5335-5339. | 3.3 | 58 |
| 135 | Regulation of vertebrate homeobox-containing genes by morphogens. , 1994, , 41-56. | | 0 |
| 136 | The thyroid transcription factor-1 gene is a candidate target for regulation by Hox proteins. EMBO Journal, 1994, 13, 3339-47. | 3.5 | 24 |
| 137 | Regulation of vertebrate homeobox-containing genes by morphogens. FEBS Journal, 1993, 212, 273-288. | 0.2 | 76 |
| 138 | Regulation of the human HOXD4 gene by retinoids. Mechanisms of Development, 1993, 44, 139-154. | 1.7 | 62 |
| 139 | Retroviral Vector-Mediated Gene Transfer into Human Primary Myogenic Cells Leads to Expression in Muscle FibersIn Vivo. Human Gene Therapy, 1993, 4, 713-723. | 1.4 | 61 |
| 140 | The upstream region of the human homeobox gene HOX3D is a target for regulation by retinoic acid and HOX homeoproteins.. EMBO Journal, 1992, 11, 265-277. | 3.5 | 77 |
| 141 | Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions. Blood, 1992, 80, 1120-1124. | 0.6 | 41 |
| 142 | The upstream region of the human homeobox gene HOX3D is a target for regulation by retinoic acid and HOX homeoproteins. EMBO Journal, 1992, 11, 265-77. | 3.5 | 33 |
| 143 | Differential regulation by retinoic acid of the homeobox genes of the four HOX loci in human embryonal carcinoma cells. Mechanisms of Development, 1991, 33, 215-227. | 1.7 | 289 |
| 144 | An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science, 1991, 251, 1363-1366. | 6.0 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | HOX gene activation by retinoic acid. Trends in Genetics, 1991, 7, 329-334. | 2.9 | 189 |
| 146 | Characterization of Two Neuroblastoma Cell Lines Expressing Recombinant Nerve Growth Factor Receptors. Journal of Neurochemistry, 1991, 56, 67-74. | 2.1 | 16 |
| 147 | Differential Activation of Homeobox Genes by Retinoic Acid in Human Embryonal Carcinoma Cells. Recent Results in Cancer Research, 1991, 123, 133-143. | 1.8 | 6 |
| 148 | Sequential activation of HOX2 homeobox genes by retinoic acid in human embryonal carcinoma cells. Nature, 1990, 346, 763-766. | 13.7 | 527 |
| 149 | Alteration of the Program of Terminal Differentiation Caused by Oncogenes in the Hemopoietic Progenitor Cell Line 32D C13 (G). Annals of the New York Academy of Sciences, 1989, 567, 154-164. | 1.8 | 9 |
| 150 | Posttranscriptional control of human homeobox gene expression in induced NTERA-2 embryonal carcinoma cells. Molecular Reproduction and Development, 1989, 1, 107-115. | 1.0 | 16 |
| 151 | Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid. Differentiation, 1988, 37, 73-79. | 1.0 | 136 |
| 152 | Differential Regulation of Transferrin Receptor Gene Expression in Human Hemopoietic Cells: Molecular and Cellular Aspects. Journal of Receptors and Signal Transduction, 1987, 7, 355-375. | 1.2 | 5 |
| 153 | Expression of Transferrin Receptors: Differential Regulatory Mechanisms in Monocytes-macrophages versus Other Hemopoietic Cells. Annals of the New York Academy of Sciences, 1987, 511, 131-137. | 1.8 | 3 |
| 154 | Expression of c-fos in Human Normal and Neoplastic Monocyte-Macrophage Differentiation. Annals of the New York Academy of Sciences, 1987, 511, 277-283. | 1.8 | 1 |
| 155 | Selective expression of fos proto-oncogene in human acute myelomonocytic and monocytic leukemias: a molecular marker of terminal differentiation. Blood, 1987, 69, 160-164. | 0.6 | 23 |
| 156 | Two human homeobox genes, c1 and c8: structure analysis and expression in embryonic development.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 4914-4918. | 3.3 | 127 |
| 157 | Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. Journal of Immunology, 1987, 138, 3829-35. | 0.4 | 262 |
| 158 | Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac---liver transition.. Journal of Clinical Investigation, 1986, 78, 51-60. | 3.9 | 265 |
| 159 | Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis.. EMBO Journal, 1986, 5, 905-911. | 3.5 | 29 |
| 160 | Expression of cellular oncogenes in primary cells from human acute leukemias.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4394-4398. | 3.3 | 64 |
| 161 | A human homoeo box gene specifically expressed in spinal cord during embryonic development. Nature, 1986, 320, 763-765. | 13.7 | 95 |
| 162 | Differential and stage-related expression in embryonic tissues of a new human homoeobox gene. Nature, 1986, 324, 664-668. | 13.7 | 208 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. EMBO Journal, 1986, 5, 905-11. | 3.5 | 15 |
| 164 | Haemoglobin switching in human embryos: asynchrony of Î¶ â†' Î± and Îµ â†' Î³-globin switches in primitive and definitive erythropoietic lineage. Nature, 1985, 313, 235-238. | 13.7 | 218 |
| 165 | A Model for Hemoglobin F Synthesis in Adult Life: Evidence for Regulation at the Level of Erythroblasts. Annals of the New York Academy of Sciences, 1985, 445, 225-234. | 1.8 | 3 |
| 166 | Association of heterocellular HPFH, beta(+)-thalassaemia, and delta beta(0)-thalassaemia: haematological and molecular aspects.. Journal of Medical Genetics, 1984, 21, 263-267. | 1.5 | 5 |
| 167 | Molecular heterogeneity of beta thalassaemia in the Italian population. British Journal of Haematology, 1984, 56, 79-85. | 1.2 | 9 |
| 168 | Heterocellular hereditary persistence of fetal hemoglobin (HPFH). Molecular mechanisms of abnormal ?-gene expression in association with ? thalassemia and linkage relationship with the ?-globin gene cluster. Human Genetics, 1984, 66, 151-156. | 1.8 | 31 |
| 169 | Translocation and rearrangement of c-myc into immunoglobulin alpha heavy chain locus in primary cells from acute lymphocytic leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 5514-5518. | 3.3 | 26 |
| 170 | Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 6907-6911. | 3.3 | 126 |
| 171 | The delta beta crossover region in Lepore boston hemoglobinopathy is restricted to a 59 base pairs region around the 5' splice junction of the large globin gene intervening sequence. Blood, 1983, 62, 230-233. | 0.6 | 18 |
| 172 | The delta beta crossover region in Lepore boston hemoglobinopathy is restricted to a 59 base pairs region around the 5' splice junction of the large globin gene intervening sequence. Blood, 1983, 62, 230-3. | 0.6 | 8 |
| 173 | | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Hb J Baltimore (Î² 16 (A13) Gly â†£ Asp) in Association with Î²-Thalassemia in a Sicilian Family. Hemoglobin, 1979, 3, 459-464. | 0.4 | 3 |
| 182 | Synthesis of HB Lepore Boston in Peripheral Blood. Hemoglobin, 1979, 3, 309-326. | 0.4 | 4 |
| 183 | Occurrence of Hb J Paris in An Italian Family and Recombination Studies on the Free Abnormal Î±-Chain. Hemoglobin, 1979, 3, 465-469. | 0.4 | 6 |
| 184 | Haemoglobin Lepore Trait: Haematological and Structural Studies on the Italian Population. British Journal of Haematology, 1979, 42, 557-565. | 1.2 | 21 |
| 185 | A new abnormal human hemoglobin: Hb prato (Î±231 (B12) Argâ†'Ser Î²2). Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1979, 578, 534-540. | 1.7 | 15 |
| 186 | Occurrence of Haemoglobin Norfolk (Î±<sub>2</sub> 57(E6) Glyâ†'Asp Î²<sub>2</sub>) at the Level of 33% in an Italian Family from Calabria. Acta Haematologica, 1979, 61, 39-46. | 0.7 | 3 |
| 187 | Hb O Indonesia (Î±2116(Gh4) Glu â†' Lys Î²2): in Association with Î²-Thalassemia. Hemoglobin, 1978, 2, 59-63. | 0.4 | 9 |
| 188 | Hemoglobin Legnano (Î±2141 (HC3) Arg â†' Leu Î²2): A New Abnormal Human Hemoglobin with High Oxygen Affinity. Hemoglobin, 1978, 2, 249-259. | 0.4 | 40 |
| 189 | Hemoglobin Gavello - Î±<sub>2</sub>Î²<sub>2</sub>47(CD6) Asp â†' Gly a new Hemoglobin Variant from Polesine (Italy). Hemoglobin, 1977, 1, 771-779. | 0.4 | 24 |